Abituzumab
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.
Link from a Wikipage to another Wikipage
primaryTopic
Abituzumab
Abituzumab is a humanized IgG2 monoclonal antibody (mAb) targeted at CD51 (an integrin) currently in development by Merck KGaA Darmstadt, Germany in an attempt to prevent bone lesion metastases in castration-resistant prostate cancer.
has abstract
Abituzumab is a humanized IgG2 ...... ion-resistant prostate cancer.
@en
CAS number
1105038-73-0
FDA UNII code
724QD330RD
Wikipage page ID
49,481,717
page length (characters) of wiki page
Wikipage revision ID
996,024,336
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
mab type
mab
@en
source
zu
@en
target
type
mab
@en
wikiPageUsesTemplate
hypernym
comment
Abituzumab is a humanized IgG2 ...... ion-resistant prostate cancer.
@en
label
Abituzumab
@en